Bio-Rad Laboratories and Invetech have announced a decade-long extension to their long-term, professional relationship in order to continue producing the BioPlex 2200. The companies first joined forces in 1998 to develop the instrument, which remains the only fully automated, random access, multiplex immunoassay testing platform for clinical in vitro diagnostics. The extension will bring the companies’ total collaboration to 25 years.
“By working with Bio-Rad through all phases of the product life-cycle, we have been able to develop a commercially viable, breakthrough product while continuing to provide extra value in continuous supply and life-cycle management of the BioPlex 2200,” said David James, senior vice president of the IVD division at Invetech. “Our highly-skilled, design, engineering and manufacturing teams are devised to be long-term partners with our customers, working with them from product concept to commercialization to obtain a competitive advantage in the marketplace.”
